Harrison W Farber

List of Publications by Year
in descending order

191	13,417	36203	22102
papers	citations	51 h-index	113 g-index

192	192	192	10376
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. Journal of the American College of Cardiology, 2009, 53, 1573-1619.	1.2	1,797
2	Pulmonary Arterial Hypertension. New England Journal of Medicine, 2004, 351, 1655-1665.	13.9	1,183
3	Pulmonary Arterial Hypertension. Chest, 2010, 137, 376-387.	0.4	1,018
4	ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. Circulation, 2009, 119, 2250-2294.	1.6	992
5	Nosocomial Pneumonia in Intubated Patients Given Sucralfate as Compared with Antacids or Histamine Type 2 Blockers. New England Journal of Medicine, 1987, 317, 1376-1382.	13.9	748
6	Predicting Survival in Patients With Pulmonary Arterial Hypertension. Chest, 2019, 156, 323-337.	0.4	408
7	Nutritional outcome and pneumonia in critical care patients randomized to gastric versus jejunal tube feedings. Critical Care Medicine, 1992, 20, 1377-1387.	0.4	361
8	Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. Journal of Clinical Investigation, 2000, 106, 483-491.	3.9	353
9	The Changing Picture of Patients With Pulmonary Arterial Hypertension in the United States. Chest, 2011, 139, 128-137.	0.4	303
10	Delay in Recognition of Pulmonary Arterial Hypertension. Chest, 2011, 140, 19-26.	0.4	228
11	Cellular glutathione peroxidase deficiency and endothelial dysfunction. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 282, H1255-H1261.	1.5	166
12	Propylene Glycol Toxicity: A Severe Iatrogenic Illness in ICU Patients Receiving IV Benzodiazepines. Chest, 2005, 128, 1674-1681.	0.4	156
13	Outcome after Cardiopulmonary Resuscitation in Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 341-344.	2.5	152
14	Sarcoidosis-Associated Pulmonary Hypertension. Chest, 2006, 130, 1481-1488.	0.4	150
15	Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Circulation, 2015, 132, 2403-2411.	1.6	140
16	Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. Chest, 2021, 159, 337-346.	0.4	137
17	Non-neuronal Enolase Is an Endothelial Hypoxic Stress Protein. Journal of Biological Chemistry, 1995, 270, 27752-27757.	1.6	133
18	Limited Systemic Sclerosis Patients with Pulmonary Arterial Hypertension Show Biomarkers of Inflammation and Vascular Injury. PLoS ONE, 2010, 5, e12106.	1.1	133

#	Article	IF	Citations
19	Imatinib Mesylate in the Treatment of Refractory Idiopathic Pulmonary Arterial Hypertension. Annals of Internal Medicine, 2006, 145, 152.	2.0	130
20	Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. Arthritis and Rheumatism, 2011, 63, 1718-1728.	6.7	125
21	Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry. Chest, 2014, 146, 1494-1504.	0.4	121
22	VEGF is deposited in the subepithelial matrix at the leading edge of branching airways and stimulates neovascularization in the murine embryonic lung. Developmental Dynamics, 2000, 219, 341-352.	0.8	116
23	Design of the REVEAL Registry for US Patients With Pulmonary Arterial Hypertension. Mayo Clinic Proceedings, 2008, 83, 923-931.	1.4	116
24	Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: Initial clinical experience. Journal of Heart and Lung Transplantation, 2013, 32, 381-387.	0.3	114
25	Comorbid Conditions and Outcomes in Patients With Pulmonary Arterial Hypertension. Chest, 2013, 144, 169-176.	0.4	113
26	Induction of heme oxygenase-1 by hypoxia and free radicals in human dermal fibroblasts. American Journal of Physiology - Cell Physiology, 2000, 278, C92-C101.	2.1	103
27	Role of free radicals in the pathogenesis of acute chest syndrome in sickle cell disease. Respiratory Research, 2001, 2, 280.	1.4	103
28	Adiponectin deficiency: a model of pulmonary hypertension associated with pulmonary vascular disease. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L432-L438.	1.3	103
29	REVEAL Registry: Correlation of Right Heart Catheterization and Echocardiography in Patients With Pulmonary Arterial Hypertension. Congestive Heart Failure, 2011, 17, 56-63.	2.0	102
30	Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. Journal of Heart and Lung Transplantation, 2015, 34, 362-368.	0.3	102
31	Identification of an oxygen responsive enhancer element in the glyceraldehyde-3-phosphate dehydrogenase gene. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1999, 1447, 208-218.	2.4	99
32	Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. American Journal of Hematology, 2015, 90, 1060-1064.	2.0	98
33	A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. Genome Medicine, 2017, 9, 27.	3.6	92
34	Pulmonary Hemodynamic Responses to Brain Natriuretic Peptide and Sildenafil in Patients With Pulmonary Arterial Hypertension. Chest, 2006, 129, 417-425.	0.4	90
35	Hypoxic regulation of endothelial glyceraldehyde-3-phosphate dehydrogenase. American Journal of Physiology - Cell Physiology, 1998, 274, C347-C355.	2.1	86
36	Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: Insights from the REVEAL Registry. Journal of Heart and Lung Transplantation, 2013, 32, 1114-1122.	0.3	86

#	Article	IF	Citations
37	ARIESâ€3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension. Cardiovascular Therapeutics, 2012, 30, 93-99.	1.1	85
38	Validation of two predictive models for survival in pulmonary arterial hypertension. European Respiratory Journal, 2015, 46, 152-164.	3.1	82
39	Systemic sclerosis-associated pulmonary hypertension: Short- and long-term effects of epoprostenol (prostacyclin). Arthritis and Rheumatism, 1999, 42, 2638-2645.	6.7	81
40	Increasing plasmalogen levels protects human endothelial cells during hypoxia. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H671-H679.	1.5	81
41	Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. Respiratory Medicine, 2005, 99, 1501-1510.	1.3	79
42	Design of the REVEAL Registry for US Patients With Pulmonary Arterial Hypertension. Mayo Clinic Proceedings, 2008, 83, 923-931.	1.4	74
43	Endothelial cell hypoxia associated proteins are cell and stress specific. Journal of Cellular Physiology, 1993, 157, 544-554.	2.0	70
44	Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1802004.	3.1	68
45	Acute changes in lipid, lipoprotein, apolipoprotein, and low-density lipoprotein particle size after an endurance triathlon. Metabolism: Clinical and Experimental, 1989, 38, 921-925.	1.5	65
46	Bloodstream Infections in Patients With Pulmonary Arterial Hypertension Treated With Intravenous Prostanoids: Insights From the REVEAL REGISTRYÂ®. Mayo Clinic Proceedings, 2012, 87, 825-834.	1.4	60
47	Propylene Glycol Toxicity in a Patient Receiving Intravenous Diazepam. New England Journal of Medicine, 2000, 343, 815-815.	13.9	58
48	Pulmonary arterial hypertension and leftâ€sided heart disease in sickle cell disease: Clinical characteristics and association with soluble adhesion molecule expression. American Journal of Hematology, 2008, 83, 547-553.	2.0	58
49	Demographics and Outcomes of Patients Diagnosed With Pulmonary Hypertension With Pulmonary Capillary Wedge Pressures 16 to 18 mm Hg. Chest, 2013, 143, 185-195.	0.4	56
50	Increased Expression of Endoplasmic Reticulum Stress and Unfolded Protein Response Genes in Peripheral Blood Mononuclear Cells From Patients With Limited Cutaneous Systemic Sclerosis and Pulmonary Arterial Hypertension. Arthritis and Rheumatism, 2013, 65, 1357-1366.	6.7	54
51	Gas 6 promotes Axl-mediated survival in pulmonary endothelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L1273-L1281.	1.3	52
52	The Accuracy of the Central Venous Blood Gas for Acid-Base Monitoring. Journal of Intensive Care Medicine, 2010, 25, 104-110.	1.3	52
53	Endothelial cell hypoxic stress proteins. Translational Research, 1998, 132, 456-463.	2.4	47
54	Effect of an endurance triathlon on pulmonary function. Medicine and Science in Sports and Exercise, 1991, 23, 1260???1264.	0.2	45

#	Article	IF	Citations
55	Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. Genome Medicine, 2021, 13, 80.	3.6	43
56	Conversion to Bosentan From Prostacyclin Infusion Therapy in Pulmonary Arterial Hypertension. Chest, 2006, 130, 1471-1480.	0.4	42
57	Sickle cell vaso-occlusive crisis induces the release of circulating serum heat shock protein-70. American Journal of Hematology, 2005, 78, 240-242.	2.0	41
58	Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension. Chest, 2018, 154, 126-135.	0.4	40
59	Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: An experience-based review. American Heart Journal, 2009, 157, 625-635.	1.2	38
60	Pulmonary Hypertension Associated with Chronic Hemolytic Anemia and Other Blood Disorders. Clinics in Chest Medicine, 2013, 34, 739-752.	0.8	37
61	Use of Selective Serotonin Reuptake Inhibitors and Outcomes in Pulmonary Arterial Hypertension. Chest, 2013, 144, 531-541.	0.4	37
62	Mycobacterium gordonae: A Possible Opportunistic Respiratory Tract Pathogen in Patients with Advanced Human Immunodeficiency Virus, Type 1 Infection. Chest, 1991, 100, 716-720.	0.4	36
63	Identification of protein disulfide isomerase as an endothelial hypoxic stress protein. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2002, 282, L996-L1003.	1.3	36
64	Gabapentin Toxicity Requiring Intubation in a Patient Receiving Long-Term Hemodialysis. Annals of Internal Medicine, 2002, 137, 74.	2.0	35
65	Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study. Chest, 2015, 147, 484-494.	0.4	35
66	Practical considerations for therapies targeting the prostacyclin pathway. European Respiratory Review, 2016, 25, 418-430.	3.0	33
67	Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. European Respiratory Journal, 2019, 54, 1901030.	3.1	33
68	Transient Pulmonary Hypertension from the Intravenous Injection of Crushed, Suspended Pentazocine Tablets. Chest, 1981, 80, 178-182.	0.4	32
69	Current Management of Primary Pulmonary Hypertension. Drugs, 2001, 61, 1945-1956.	4.9	31
70	The Status of Pulmonary Arterial Hypertension in 2008. Circulation, 2008, 117, 2966-2968.	1.6	30
71	Fatal Outcome following Nifedipine for Pulmonary Hypertension. Chest, 1983, 83, 708-709.	0.4	29
72	REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. Journal of Heart and Lung Transplantation, 2018, 37, 836-843.	0.3	29

#	Article	IF	Citations
73	REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. Journal of Heart and Lung Transplantation, 2018, 37, 513-519.	0.3	29
74	Endothelial cell nitric oxide production in acute chest syndrome. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 277, H1579-H1592.	1.5	28
75	Prothrombotic mechanisms in primary pulmonary hypertension. Translational Research, 1999, 134, 561-566.	2.4	28
76	Identification of oxidative post-translational modification of serum albumin in patients with idiopathic pulmonary arterial hypertension and pulmonary hypertension of sickle cell anemia. Rapid Communications in Mass Spectrometry, 2007, 21, 2195-2203.	0.7	28
77	Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. Journal of Heart and Lung Transplantation, 2018, 37, 696-705.	0.3	28
78	The endurance triathlon. Medicine and Science in Sports and Exercise, 1991, 23, 959???965.	0.2	27
79	Induction of endothelial cell cytoplasmic lipid bodies during hypoxia. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 280, H294-H301.	1.5	27
80	Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 751-760.	2.5	27
81	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. Chest, 2020, 157, 955-965.	0.4	26
82	Assessing risk in pulmonary arterial hypertension: what we know, what we don't. European Respiratory Journal, 2017, 50, 1701353.	3.1	25
83	Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. Journal of Heart and Lung Transplantation, 2019, 38, 43-50.	0.3	25
84	United States Pulmonary Hypertension Scientific Registry. Chest, 2021, 159, 311-327.	0.4	25
85	Atenolol-induced cardiovascular collapse treated with hemodialysis. Critical Care Medicine, 1991, 19, 116-117.	0.4	24
86	Pulmonary hypertension and Î²-thalassemia major: Report of a case, its treatment, and a review of the literature. American Journal of Hematology, 2006, 81, 443-447.	2.0	24
87	Under pressure: pulmonary hypertension associated with left heart disease. European Respiratory Review, 2015, 24, 665-673.	3.0	24
88	On the importance of plasmalogen status in stimulated arachidonic acid release in the macrophage cell line RAW 264.7. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2008, 1781, 213-219.	1.2	23
89	Serotonin-stimulated aortic endothelial cells secrete a novel T lymphocyte chemotactic and growth factor. Journal of Leukocyte Biology, 1994, 55, 567-573.	1.5	22
90	Successful Treatment of Chylous Ascites Secondary To Mycobacterium Avium Complex in A Patient With The Acquired Immune Deficiency Syndrome. American Journal of Gastroenterology, 1999, 94, 1689-1690.	0.2	22

#	Article	IF	Citations
91	Effect of long-term hypoxia on cultured aortic and pulmonary arterial endothelial cells. Experimental Cell Research, 1990, 191, 27-36.	1.2	21
92	Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease. New England Journal of Medicine, 2004, 350, 2521-2522.	13.9	19
93	Differential gene expression in pulmonary artery endothelial cells exposed to sickle cell plasma. Physiological Genomics, 2005, 21, 293-298.	1.0	19
94	Cardiopulmonary Exercise Testing with Right-heart Catheterization in Patients with Systemic Sclerosis. Journal of Rheumatology, 2010, 37, 1871-1877.	1.0	19
95	Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis. Arthritis Research and Therapy, 2018, 20, 185.	1.6	19
96	Prevalence and Mortality of Pulmonary Hypertension in ESRD: A Systematic Review and Meta-analysis. Lung, 2020, 198, 535-545.	1.4	19
97	Immune Restoration Syndrome Manifested by Pulmonary Sarcoidosis. American Journal of Roentgenology, 2001, 177, 1427-1427.	1.0	18
98	Pulmonary hypertension. Current Opinion in Rheumatology, 2011, 23, 536-544.	2.0	18
99	Validation of the 6-Minute Walk in Patients With Pulmonary Arterial Hypertension. Circulation, 2012, 126, 258-260.	1.6	18
100	Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL. Journal of Heart and Lung Transplantation, 2018, 37, 948-955.	0.3	18
101	Endothelial hypoxic stress proteins. Kidney International, 1997, 51, 426-437.	2.6	16
102	Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review. Journal of Heart and Lung Transplantation, 2021, 40, 172-182.	0.3	16
103	Effect of Hypoxia on Endothelial Cell Surface Glycoprotein Expression: Modulation of Glycoprotein IIIa and Other Specific Surface Glycoproteins. Experimental Cell Research, 1993, 208, 465-478.	1.2	15
104	The Closed Tracheal Suction System. Dimensions of Critical Care Nursing, 1994, 13, 292-300.	0.4	15
105	Relation of Novel Echocardiographic Measures to Invasive Hemodynamic Assessment in Sclerodermaâ€Associated Pulmonary Arterial Hypertension. Arthritis Care and Research, 2014, 66, 1386-1394.	1.5	15
106	The HLA-B*35 allele modulates ER stress, inflammation and proliferation in PBMCs from Limited Cutaneous Systemic Sclerosis patients. Arthritis Research and Therapy, 2015, 17, 363.	1.6	15
107	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI 2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. Journal of Heart and Lung Transplantation, 2018, 37, 401-408.	0.3	15
108	Pulmonary Response to Foreign Body Microemboli in Dogs: Release of Neutrophil Chemoattractant Activity by Vascular Endothelial Cells. American Journal of Respiratory Cell and Molecular Biology, 1989, 1, 27-35.	1.4	14

#	Article	IF	Citations
109	Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction: Acute Hemodynamic Effects of Inhaled Iloprost. Pulmonary Circulation, 2015, 5, 198-203.	0.8	14
110	Replacing a phosphodiesteraseâ€5Âinhibitor with riociguat in patients with connective tissue diseaseâ€associated pulmonary arterial hypertension: a case series. Pulmonary Circulation, 2017, 7, 741-746.	0.8	13
111	Prevalence and Hospital Discharge Status of Human Immunodeficiency Virusâ€“Associated Pulmonary Arterial Hypertension in the United States. Pulmonary Circulation, 2015, 5, 506-512.	0.8	12
112	Novel investigational therapies for treating pulmonary arterial hypertension. Expert Opinion on Investigational Drugs, 2015, 24, 1571-1596.	1.9	12
113	Patients with systemic sclerosis-associated pulmonary arterial hypertension express a genomic signature distinct from patients with interstitial lung disease. Journal of Scleroderma and Related Disorders, 2018, 3, 242-248.	1.0	12
114	Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-11.	0.8	12
115	Human Pulmonary Dirofilarial Infection. Annals of Internal Medicine, 1987, 106, 777.	2.0	11
116	Synthesis and biological properties of the fluorescent ether lipid precursor 1-O-[9â€²-(1â€³-pyrenyl)]nonyl-sn-glycerol. Journal of Lipid Research, 2006, 47, 633-642.	2.0	11
117	Analytic Review: Care of Patients With Scleroderma in the Intensive Care Setting. Journal of Intensive Care Medicine, 2010, 25, 247-258.	1.3	10
118	Using Clinical Trial End Points to Risk Stratify Patients With Pulmonary Arterial Hypertension. Circulation, 2015, 132, 2152-2161.	1.6	10
119	The New World Symposium on Pulmonary Hypertension Guidelines. Circulation, 2019, 140, 1134-1136.	1.6	10
120	Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE. Journal of Heart and Lung Transplantation, 2021, 40, 279-288.	0.3	10
121	Gallium Scans and Serum Angiotensin Converting Enzyme Levels in Talc Granulomatosis and Lymphocytic Interstitial Pneumonitis. Southern Medical Journal, 1980, 73, 1663-1666.	0.3	9
122	Effect of sodium butyrate on lung vascular TNFSF15 (TL1A) expression: Differential expression patterns in pulmonary artery and microvascular endothelial cells. Cytokine, 2009, 46, 72-78.	1.4	9
123	Pulmonary vasculitis in Hughes-Stovin syndrome (HSS): a reference atlas and computed tomography pulmonary angiography guideâ€”a report by the HSS International Study Group. Clinical Rheumatology, 2021, 40, 4993-5008.	1.0	9
124	Acute Cardiopulmonary Hemodynamic Effects of Brain Natriuretic Peptide in Patients With Pulmonary Arterial Hypertension. Chest, 2005, 128, 618S-619S.	0.4	8
125	Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension. Pulmonary Pharmacology and Therapeutics, 2011, 24, 421-425.	1.1	8
126	Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration. Annals of the American Thoracic Society, 2015, 12, 269-273.	1.5	8

#	Article	IF	Citations
127	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005095.	0.9	8
128	The Effect of Oral Hydralazine on the Pulmonary Hemodynamics of Patients with Pulmonary Foreign Body Granulomatosis. Chest, 1982, 82, 708-712.	0.4	7
129	Ranolazine for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction: A pilot study. Journal of Heart and Lung Transplantation, 2016, 35, 1370-1373.	0.3	7
130	Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1513-1520.	1.5	7
131	Changes in gene expression profiles in patients with pulmonary arterial hypertension associated with scleroderma treated with tadalafil. Seminars in Arthritis and Rheumatism, 2017, 46, 465-472.	1.6	7
132	Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway. Lung, 2019, 197, 761-768.	1.4	7
133	United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications. Pulmonary Circulation, 2019, 9, 204589401985169.	0.8	7
134	Barriers to frostbite treatment at an academic medical center. American Journal of Emergency Medicine, 2019, 37, 1601.e3-1601.e5.	0.7	7
135	Management of hospitalized patients with pulmonary arterial hypertension and COVIDâ€19Âinfection. Pulmonary Circulation, 2020, 10, 1-5.	0.8	7
136	Pulmonary Hypertension in Chronic Kidney Disease. Cardiology Clinics, 2021, 39, 427-434.	0.9	7
137	Pulmonary Arterial Hypertension. Chest, 2021, 160, 1981-1983.	0.4	7
138	Successful Bosentan and Nonnucleoside Reverse Transcriptase Inhibitorâ€“Based Therapy in a Patient with Acquired Immunodeficiency Syndrome and Pulmonary Arterial Hypertension. Pharmacotherapy, 2010, 30, 422-422.	1.2	6
139	Ethical issues associated with globalization of placebo-controlled in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2010, 29, 825-826.	0.3	6
140	Ophthalmologic Diagnosis of Exacerbation of Idiopathic Pulmonary Arterial Hypertension. JAMA Ophthalmology, 2012, 130, 1619.	2.6	6
141	Treatment of pulmonary hypertension in patients with Hereditary Hemorrhagic Telangiectasia â€“ A case series and systematic review. Pulmonary Pharmacology and Therapeutics, 2021, 68, 102033.	1.1	6
142	Endotracheal Reintubation: A Closer Look at a Preventable Condition. Clinical Nurse Specialist, 1997, 11, 145-150.	0.3	6
143	Use of ultrasound-measured internal jugular vein collapsibility index to determine static intracardiac pressures in patients with presumed pulmonary hypertension. Annals of Intensive Care, 2019, 9, 124.	2.2	6
144	Effects of Endothelial Cell Injury on Pulmonary Vascular Reactivity. Chest, 1985, 88, 213S-216S.	0.4	5

#	Article	IF	Citations
145	Pharmacokinetic evaluation of treprostinil (oral) for the treatment of pulmonary arterial hypertension. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1445-1453.	1.5	5
146	Gestational Pulmonary Arterial Hypertension. Pulmonary Circulation, 2015, 5, 730-733.	0.8	5
147	Clinical trial design in phase 2 and 3 trials for pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-10.	0.8	5
148	A pilot study of dimethyl fumarate in pulmonary arterial hypertension associated with systemic sclerosis. Journal of Scleroderma and Related Disorders, 2021, 6, 242-246.	1.0	5
149	Effect of hypercarbia on surface proteins of cultured bovine endothelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1997, 273, L1141-L1146.	1.3	4
150	Early Pulmonary Embolectomy for Acute Pulmonary Embolus: An Operation Whose Time Has Come. Journal of Cardiac Surgery, 2010, 25, 259-260.	0.3	4
151	Pulmonary hypertension associated with left ventricular diastolic dysfunction. Journal of Heart and Lung Transplantation, 2010, 29, 230-231.	0.3	4
152	Quality initiatives and models of care in patients with pulmonary arterial hypertension: The time has come!. International Journal of Clinical Practice, 2011, 65, 1-3.	0.8	4
153	Secretion of a Novel T-Lymphocyte Cytokine Possessing both Chemotactic and Growth Factor Activity by Serotonin-Stimulated Human Aortic Endothelial Cells. Experimental Cell Research, 1994, 212, 113-119.	1.2	3
154	Propylene Glycol Accumulation During Continuous-infusion Lorazepam in Critically Ill Patients. Journal of Intensive Care Medicine, 2008, 23, 413-413.	1.3	3
155	Swan-Ganz and Pericardial Pressureâ€“guided Pericardiocentesis in Pulmonary Arterial Hypertensionâ€“associated Cardiac Tamponade. Annals of the American Thoracic Society, 2019, 16, 1189-1191.	1.5	3
156	Pulmonary Arterial Hypertension and Specialty Care Centers. Chest, 2020, 158, 28-30.	0.4	3
157	Stress Cardiomyopathy Precipitated by Withdrawal of Epoprostenol. JACC: Case Reports, 2020, 2, 289-293.	0.3	3
158	Pulmonary Arterial Hypertension in Patients Infected with the Human Immunodeficiency Virus. Cardiology Clinics, 2022, 40, 45-54.	0.9	3
159	Micrococcus bacteremia in a patient with pulmonary hypertension and a long-term central venous catheter: Opportunity knocks, and an unexpected pathogen enters. Clinical Microbiology Newsletter, 2007, 29, 173-175.	0.4	2
160	Cause of death in patients with pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2014, 33, 222.	0.3	2
161	Anti-coagulation in pulmonary arterial hypertension: the real blood and guts. Journal of Thoracic Disease, 2016, 8, E1106-E1107.	0.6	2
162	Pulmonary Veno-Occlusive Disease. Circulation, 2017, 136, 2034-2036.	1.6	2

#	Article	IF	Citations
163	Pulmonary Tumor Thrombotic Microangiopathy as a Cause of Pulmonary Hypertension. JACC: Case Reports, 2021, 3, 1029-1031.	0.3	2
164	Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, 184-191.	0.2	2
165	Effects of Hypoxia and Hypercarbia on Cultured Endothelial Cells. Chest, 1988, 93, 156S-157S.	0.4	1
166	Production of neutrophil-specific lipid chemoattractant activity by cultured endothelial cells: Heterogeneity dependent on species, ligand, or endothelial cell site of origin. Tissue and Cell, 1992, 24, 355-366.	1.0	1
167	IV Epoprostenol for Systemic Sclerosis. Chest, 2000, 118, 881-882.	0.4	1
168	Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2006, 355, 1828-1831.	13.9	1
169	A COMPARISON OF REVEAL REGISTRY DEMOGRAPHIC DATA WITH OTHER/PRIOR REGISTRIES OF PULMONARY ARTERIAL HYPERTENSION (PAH). Chest, 2008, 134, 134P.	0.4	1
170	Add-on parenteral therapy in pulmonary arterial hypertension: The good, the bad, and the ugly. Journal of Heart and Lung Transplantation, 2019, 38, 1003-1005.	0.3	1
171	Unilateral Chronic Thromboembolic Pulmonary Disease: A Mimic of Pulmonary Artery Agenesis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, e74-e75.	2.5	1
172	Pathophysiology of Pulmonary Arterial Hypertension. , 2008, , 51-72.		1
173	Patient Registries in Pulmonary Arterial Hypertension: the Role of Survival Equations and Risk Calculators. , 2016, , 307-325.		1
174	Pulmonary hypertension secondary to takayasu's arteritis: management using a combined medical and interventional approach. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, 239-241.	0.2	1
175	Mechanism of disease: Pulmonary hypertension. Discovery Medicine, 2005, 5, 80-7.	0.5	1
176	Application of the REVEAL risk score calculator 2.0 in the CHEST study. Respiratory Medicine, 2022, 195, 106783.	1.3	1
177	Pulmonary Circulation: Diseases and Their Treatment. Circulation, 2006, 113, .	1.6	0
178	The Role of Aldosterone in Pulmonary Venous Hypertension. Chest, 2010, 137, 502.	0.4	0
179	Clinical Assessment of Pulmonary Hypertension. , 2012, , 429-435.		0
180	Pulmonary Cavity From Mycobacterium malmoense in an HIV-Infected Patient: Complicated by Bronchopleural Fistula. Open Forum Infectious Diseases, 2018, 5, ofy023.	0.4	0

#	Article	IF	Citations
181	Response. Chest, 2018, 154, 1262-1264.	0.4	0
182	Pharmacokinetics of ambrisentan in a patient with Pulmonary Arterial Hypertension and a total gastrectomy. Pulmonary Pharmacology and Therapeutics, 2019, 57, 101813.	1.1	0
183	A Man with End-Stage Renal Disease, Dyspnea, and an Abnormal Echocardiogram. Annals of the American Thoracic Society, 2019, 16, 1577-1581.	1.5	0
184	Severe Digit Ischemia Associated with Scleroderma: a Case Report and Treatment Guide. SN Comprehensive Clinical Medicine, 2021, 3, 306-308.	0.3	0
185	A Sickle Transgenic Mouse Model of Acute Chest Syndrome.. Blood, 2004, 104, 3585-3585.	0.6	0
186	Identification of Oxidative Post-Translational Modifications on Plasma Albumin in Patients with Pulmonary Hypertension of Sickle Cell Anemia.. Blood, 2006, 108, 1215-1215.	0.6	0
187	Clinical Assessment of Pulmonary Hypertension. , 2017, , 403-409.		0
188	Gaps and Controversies of New Treatment Recommendations in Recent Pulmonary Hypertension Guidelines: What We Know and What We Don't. Advances in Pulmonary Hypertension, 2017, 16, 20-25.	0.1	0
189	PH Grand Rounds: A Case of Pulmonary Hypertension Associated With High Cardiac Output State from Arteriovenous Fistulaâ€“Or Is It?. Advances in Pulmonary Hypertension, 2019, 18, 70-73.	0.1	0
190	Connective Tissue Disease Associated Pulmonary Hypertension. , 2008, , 145-171.		0
191	Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, 234-238.	0.2	0